Clinical use of recombinant tissue plasminogen activator for anterior chamber fibrinolysis.
In a preliminary clinical study, 12.5 micrograms/100 microliters of recombinant tissue plasminogen activator (rt-PA) was injected into the anterior chamber of 3 eyes of 3 patients who suffered from excessive post-operative fibrin formation. The prominent fibrinolytic effect was achieved without any side effect. Rt-PA is an effective and safe regimen for the management of excessive post-operative intraocular fibrin formation.
Lin
C P
CP
Department of Ophthalmology, Kaohsiung Medical College, Taiwan, Republic of China.
D000368:Aged; D000867:Anterior Chamber / Q000187:drug effects*; D002648:Child; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator